US Bancorp
DFTX

US Bancorp’s Definium Therapeutics DFTX Stock Holding History

US Bancorp’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-66
Closed -$242 – 4051
2023
Q4 		$242 Hold
66
– – ﹤0.01% 3900
2023
Q3 		$207 Hold
66
– – ﹤0.01% 3909
2023
Q2 		$236 Hold
66
– – ﹤0.01% 3916
2023
Q1 		$209 Buy
+66
New +$219 ﹤0.01% 4019
2022
Q3 		– Sell
-133
Closed -$1K – 4157
2022
Q2 		$1K Hold
133
– – ﹤0.01% 3975
2022
Q1 		$2K Hold
133
– – ﹤0.01% 3845
2021
Q4 		$3K Hold
133
– – ﹤0.01% 3812
2021
Q3 		$5K Buy
+133
New +$5.75K ﹤0.01% 3649

Other funds holding DFTX

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
ABG
Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

US Bancorp's DFTX Position: Q1 2024 in Review

US Bancorp sold out of Definium Therapeutics (DFTX) in Q1 2024, closing a stake of 66 shares — an estimated $242 sold.

US Bancorp first reported a position in DFTX in Q3 2021 and held it in 8 quarters. The position peaked at $5K in Q3 2021. 135 funds tracked by Wall St. Rank hold DFTX as of Q1 2024.

  • US Bancorp reported no remaining Definium Therapeutics position as of Q1 2024 after selling out during the quarter.
  • US Bancorp sold 66 Definium Therapeutics shares in Q1 2024, an estimated $242.
  • US Bancorp first reported a position in Definium Therapeutics in Q3 2021 and held it in 8 quarters.
  • US Bancorp's Definium Therapeutics position peaked at $5K in Q3 2021.
  • 135 funds tracked by Wall St. Rank held Definium Therapeutics as of Q1 2024.

Based on US Bancorp's 13F filing for Q1 2024, filed 8 May 2024.